Sleep studies regularly identify patients who have not developed OSA to a degree that justifies CPAP therapy.
While a dental appliance (MAD) for relief from primary snoring or mild sleep apnea may suit some of these patients, many just want an OTC, low cost, effective snoring product.
Offering patients sleepQ+ provides another option to primary snorers and sufferers of mild sleep apnoea who are looking for a solution until the problem becomes more complex, or develops into OSA, and an opportunity for the clinician to maintain contact with patients and nurture relationships during repeat visits for more sleepQ+.
sleepQ+ also prevents mouth leak or venting during CPAP therapy, which can cause dryness in the mouth and throat and painful sinus congestion.
sleepQ+ is made in the US to FDA manufacturing standards and is registered with the Australian Therapeutic Goods Administration (TGA), Health Canada and Medsafe New Zealand.
Two specific studies evaluating the safety of sleepQ+ for use in humans have been performed.
Sensitivity and Irritation – 54 subjects. Skin Patch Sensitivity Study by Cantor Research Laboratories Inc of Blauvelt, NY, USA following the principles referenced in “Appraisal of the Safety of Chemicals in Food, Drugs and Cosmetics” published by the US FDA.
No adverse reactions of any kind were observed during the course of the study. It was concluded that the reversible oral adhesive gel is a non-primary irritant and a non-primary sensitizer.
Toxicity Study – by AMS Laboratories Pty Ltd of Silverwater NSW Australia according to ISO 10993-5 (2002) and AS/NZS 26961996)
The reversible oral adhesive gel was found to be non-cytotoxic.
sleepQ+ is made in the US to FDA manufacturing standards and is registered with the Australian Therapeutic Goods Administration (TGA), Health Canada and Medsafe New Zealand for preventing involuntary mouth breathing during sleep.
To arrange your supply of this unique product at our wholesale rate or for more information email us at email@example.com.
Updated 25 October 2020